Budesonide is retained in the airways longer than mometasone furoate due to the reversible formation of lipophilic budesonide fatty acid esters - significance for asthma therapy Source: Eur Respir J 2002; 20: Suppl. 38, 53s Year: 2002
Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on human airway inflammation Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Comparison of inhaled ciclesonide, fluticasone propinate and fluticasone propionate + salmeterol in maintaining asthma control Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Mometasone furoate is a less specific glucocorticoid than fluticasone propionate Source: Eur Respir J 2002; 20: 1386-1392 Year: 2002
Fluticasone propionate is as potent but more receptor-selective than mometasone furoate Source: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
The potency ratio fluticasone propionate / budesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Higher cellular retention and activity after pulse exposure by budesonide (BUD) than fluticasone propionate (FP) and mometasone furoate (MF) Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001
Timecourse of action of two inhaled corticosteroids, fluticasone propionate and budesonide Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002
A comparison of fluticasone propionate (FP) and mometasone furoate (MF) nasal spray in the treatment of nasal polyposis associated with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on neuronal inflammation and acetylcholine release Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Source: Eur Respir J 2014; 43: 773-782 Year: 2014
In vitro metabolism of ciclesonide, beclomethasone dipropionate, budesonide and fluticasone propionate in human precision-cut lung slicesSource: Eur Respir J 2005; 26: Suppl. 49, 255s Year: 2005
A superior improvement in lung function in patients with moderate persistent asthma is seen with mometasone furoate 200 μg b.i.d delivered by dry powder inhaler compared with beclomethasone dipropionate 168 μg Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R) Source: Eur Respir J 2001; 17: 1332-1333 Year: 2001
Airway and systemic effects of hydrofluoroalkane formulations of high dose ciclesonide and fluticasone propionate in moderate persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004
Budesonide and formoterol in a single inhaler quickly gains asthma control compared with fluticasone propionate in mild asthma Source: Eur Respir J 2001; 18: Suppl. 33, 48s Year: 2001
Characterization of airflow properties of the mometasone furoate dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001
Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003